Business Description
Editas Medicine Inc
NAICS : 325412
SIC : 2834
ISIN : US28106W1036
Compare
Compare
Traded in other countries / regions
8EM.Germany0IFK.UKEDIT.USA IPO Date
2016-02-03Description
Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.58 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.65 | |||||
| Beneish M-Score | -4.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -11.3 | |||||
| 3-Year EBITDA Growth Rate | -5 | |||||
| 3-Year EPS without NRI Growth Rate | -6.2 | |||||
| 3-Year FCF Growth Rate | -41.3 | |||||
| 3-Year Book Growth Rate | 2.8 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.72 | |||||
| 9-Day RSI | 46.08 | |||||
| 14-Day RSI | 51.05 | |||||
| 6-1 Month Momentum % | -21.24 | |||||
| 12-1 Month Momentum % | -27.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.68 | |||||
| Quick Ratio | 5.68 | |||||
| Cash Ratio | 5.57 | |||||
| Days Sales Outstanding | 24.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -992.33 | |||||
| Net Margin % | -960.7 | |||||
| ROE % | -52.86 | |||||
| ROA % | -40.35 | |||||
| ROIC % | -148.34 | |||||
| ROC (Joel Greenblatt) % | -503.98 | |||||
| ROCE % | -45.58 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 27.41 | |||||
| PB Ratio | 1.98 | |||||
| Price-to-Tangible-Book | 1.98 | |||||
| EV-to-EBIT | -1.53 | |||||
| EV-to-Forward-EBIT | -1.54 | |||||
| EV-to-EBITDA | -1.58 | |||||
| EV-to-Forward-EBITDA | -1.6 | |||||
| EV-to-Revenue | 15.21 | |||||
| EV-to-Forward-Revenue | 11.18 | |||||
| EV-to-FCF | -2.07 | |||||
| Price-to-Net-Current-Asset-Value | 3.53 | |||||
| Price-to-Net-Cash | 3.65 | |||||
| Earnings Yield (Greenblatt) % | -65.36 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EDIT
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Editas Medicine Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 22.791 | ||
| EPS (TTM) ($) | -3.18 | ||
| Beta | 1.97 | ||
| Volatility % | 56.37 | ||
| 14-Day RSI | 51.05 | ||
| 14-Day ATR ($) | 0.600601 | ||
| 20-Day SMA ($) | 9.34025 | ||
| 12-1 Month Momentum % | -27.26 | ||
| 52-Week Range ($) | 6.33 - 19.97 | ||
| Shares Outstanding (Mil) | 69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Editas Medicine Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Editas Medicine Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Editas Medicine Inc Frequently Asked Questions
What is Editas Medicine Inc(EDIT)'s stock price today?
The current price of EDIT is $9.10. The 52 week high of EDIT is $19.97 and 52 week low is $6.33.
When is next earnings date of Editas Medicine Inc(EDIT)?
The next earnings date of Editas Medicine Inc(EDIT) is 2023-08-03 Est..
Does Editas Medicine Inc(EDIT) pay dividends? If so, how much?
Editas Medicine Inc(EDIT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
